Physician profile
Emily Easterly
NPI 1841032414
$3,481.71
in general payments reported to CMS, 2019-2025
16 companies · $2,411 in 2025
The $2,411 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,071 · 2025: $2,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,383 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,382.71 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $859.67 | 2024-2025 | Krystexxa, Evenity, Tavneos |
| Abbvie INC. | $571.38 | 2024-2025 | |
| Janssen Biotech, INC. | $471.46 | 2024-2025 | Tremfya, Remicade, Simponi Aria |
| Genzyme Corporation | $333.89 | 2024-2025 | |
| Ucb, INC. | $287.78 | 2024-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $242.18 | 2024-2025 | |
| Pfizer INC. | $141.83 | 2025 | |
| Sandoz INC. | $131.84 | 2024-2025 | Hyrimoz |
| Glaxosmithkline, LLC. | $98.18 | 2024-2025 | Benlysta, Nucala |
| Genentech USA, INC. | $92.46 | 2024-2025 | Actemra, Gazyva |
| Astrazeneca Pharmaceuticals LP | $82.41 | 2024-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $65.59 | 2025 | Orencia |
| Lilly USA, LLC | $50.84 | 2024 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.28 | 2024 | Synjardy, Jardiance |
| Radius Health, INC. | $15.14 | 2024 | Tymlos |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $14.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Easterly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.